Psoriatic arthritis (PsA) often coexists with metabolic syndrome (MetS), with both conditions sharing a pro-inflammatory profile and contributing to increased disease burden and treatment complexity. MetS is more prevalent in PsA than in other inflammatory arthritides, and obesity-related factors are linked to a higher risk of developing PsA, while weight loss has been shown to reduce disease activity. Treatments for PsA can influence MetS components, and emerging therapies targeting weight loss may offer additional benefits when combined with PsA management.

Reference: Williams JC, Hum RM, Rogers K, et al. Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis. 2024 Aug 19;16:1759720X241271886. doi: 10.1177/1759720X241271886. PMID: 39161788; PMCID: PMC11331474.